X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (52) 52
index medicus (46) 46
hematology (34) 34
female (27) 27
leukemia (25) 25
oncology (25) 25
male (24) 24
acute myeloid leukemia (23) 23
aged (21) 21
leukemia, myeloid, acute - drug therapy (20) 20
middle aged (18) 18
acute myeloid-leukemia (17) 17
animals (15) 15
mutation (15) 15
aml (14) 14
aged, 80 and over (13) 13
article (13) 13
cell biology (12) 12
chemotherapy (12) 12
leukemia, myeloid, acute - genetics (12) 12
leukemia, myeloid, acute - pathology (12) 12
adult (11) 11
mice (11) 11
myeloid leukemia (11) 11
older patients (11) 11
patients (11) 11
prognosis (10) 10
cancer (9) 9
leukemia, myeloid, acute - metabolism (9) 9
treatment outcome (9) 9
abridged index medicus (8) 8
hemic and lymphatic diseases (8) 8
leukemia, myeloid, acute - diagnosis (8) 8
myelodysplastic syndrome (8) 8
stem cells (8) 8
acute myelogenous leukemia (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
differentiation (7) 7
mutations (7) 7
research (7) 7
stem-cells (7) 7
transplantation (7) 7
venetoclax (7) 7
antineoplastic agents - therapeutic use (6) 6
cytarabine (6) 6
leukemia, myeloid, acute - mortality (6) 6
leukemia, myeloid, acute - therapy (6) 6
myelodysplastic syndromes (6) 6
open-label (6) 6
abt-199 (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
biochemistry & molecular biology (5) 5
cell line, tumor (5) 5
colony-stimulating factor (5) 5
inhibition (5) 5
intensive chemotherapy (5) 5
international working group (5) 5
metabolism (5) 5
neoplastic stem cells - pathology (5) 5
oxidative stress (5) 5
remission (5) 5
remission induction (5) 5
risk factors (5) 5
young adult (5) 5
analysis (4) 4
apoptosis (4) 4
bone-marrow (4) 4
conventional care regimens (4) 4
dasatinib (4) 4
dose-response relationship, drug (4) 4
gemtuzumab ozogamicin (4) 4
gene mutations (4) 4
gene-expression (4) 4
genetic aspects (4) 4
health aspects (4) 4
hematopoiesis (4) 4
hematopoietic stem cell transplantation (4) 4
hematopoietic stem cells (4) 4
minimal residual disease (4) 4
myelodysplastic syndromes - drug therapy (4) 4
myelodysplastic syndromes - genetics (4) 4
myelodysplastic syndromes - therapy (4) 4
nuclear proteins - genetics (4) 4
receptor-alpha chain (4) 4
recurrence (4) 4
risk (4) 4
survival (4) 4
survival analysis (4) 4
survival rate (4) 4
therapeutic strategy (4) 4
tumors (4) 4
usage (4) 4
5-aza-2'-deoxycytidine (3) 3
abt-737 (3) 3
administration, oral (3) 3
adolescent (3) 3
adult patients (3) 3
adults (3) 3
age factors (3) 3
antimitotic agents (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 09/2019, Volume 19, pp. S87 - S88
Journal Article
American Journal of Hematology, ISSN 0361-8609, 2019, Volume 94, Issue 9, pp. 959 - 962
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2018, Volume 24, Issue 23, pp. 5790 - 5791
Clonal hematopoiesis is common, and the large-scale sequencing of patients' tumors in the clinical setting is becoming very common. The incidence of falsely... 
ONCOLOGY | CLONAL HEMATOPOIESIS
Journal Article
Clinical Lymphoma Myeloma and Leukemia, ISSN 2152-2650, 09/2017, Volume 17, pp. S112 - S114
Journal Article
Hematology. American Society of Hematology. Education Program, ISSN 1520-4391, 11/2018, Volume 2018, Issue 1, pp. 45 - 50
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2018
Journal Article
Best Practice & Research Clinical Haematology, ISSN 1521-6926, 12/2018, Volume 31, Issue 4, pp. 391 - 395
There has been little progress in drug development in acute myeloid leukemia (AML) in the recent past. This recently changed with the approval of several... 
AML | Novel | Practice changing | Standard of care | Acute myeloid leukemia | STEM-CELLS | FLT3 | MIDOSTAURIN | PHASE-2 | ADULT | TRIAL | INHIBITION | MUTATIONS | HEMATOLOGY | ENASIDENIB | Antimitotic agents | Antineoplastic agents
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 19, pp. 1781 - 1790
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2018, Volume 24, Issue 20, pp. 4931 - 4936
Acute myeloid leukemia (AML) is an aggressive disease with a poor prognosis. A large percentage of patients succumb to this disease in spite of aggressive... 
SURVIVAL | SUPPORTIVE CARE | GEMTUZUMAB OZOGAMICIN | OLDER PATIENTS | ONCOLOGY | MUTANT IDH2 | 2 MUTATIONS | ISOCITRATE-DEHYDROGENASE 1 | OPEN-LABEL | PROGNOSTIC-SIGNIFICANCE | ONCOMETABOLITE 2-HYDROXYGLUTARATE
Journal Article
The Lancet Oncology, ISSN 1470-2045, 02/2018, Volume 19, Issue 2, pp. 216 - 228
Journal Article
Blood, ISSN 0006-4971, 08/2017, Volume 130, Issue 6, pp. 722 - 731
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2018, Volume 378, Issue 25, pp. 2386 - 2398
Among patients with IDH1 -mutated relapsed or refractory leukemia, daily oral ivosidenib, an IDH1 inhibitor, induced molecular clearance of leukemic cells from... 
MEDICINE, GENERAL & INTERNAL | IDH2 MUTATIONS | METAANALYSIS | ACUTE MYELOID-LEUKEMIA | PROGNOSTIC-SIGNIFICANCE | DIFFERENTIATION | INHIBITOR | Glycine - analogs & derivatives | Recurrence | Follow-Up Studies | Glycine - adverse effects | Cell Count | Humans | Middle Aged | Pyridines - pharmacokinetics | Drug Resistance, Neoplasm | Male | Isocitrate Dehydrogenase - antagonists & inhibitors | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Young Adult | Pyridines - adverse effects | Enzyme Inhibitors - pharmacokinetics | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Glycine - administration & dosage | Enzyme Inhibitors - adverse effects | Glycine - pharmacokinetics | Pyridines - administration & dosage | Administration, Oral | Isocitrate Dehydrogenase - genetics | Survival Rate | Remission Induction | Leukemia, Myeloid, Acute - mortality | Adolescent | Aged | Mutation | Hemoglobins - analysis | Leukemia, Myeloid, Acute - genetics | Usage | Myelocytic leukemia | Gene mutations | Physiological aspects | Genetic aspects | Nonlymphoid leukemia | Research | Drug therapy | Isocitrate dehydrogenase | Risk factors | Thrombocytopenia | Myeloid leukemia | Leukemia | FDA approval | Cancer therapies | Patients | Investigations | Leukocytosis | Collaboration | Point mutation | Remission | Acute myeloid leukemia | Drug dosages | Neutropenia | Tumors
Journal Article
Current Opinion in Hematology, ISSN 1065-6251, 03/2019, Volume 26, Issue 2, pp. 71 - 76
PURPOSE OF REVIEWVenetoclax with backbone therapies have shown promising efficacy for newly diagnosed, previously untreated, older, unfit acute myeloid... 
BCL-2 | cytarabine | STEM-CELLS | acute myeloid leukemia | ABT-737 | ACUTE MYELOID-LEUKEMIA | hypomethylator | venetoclax | HEMATOLOGY | ABT-199 | Usage | Dosage and administration | Cytarabine | Drug therapy, Combination
Journal Article
Cancer Cell, ISSN 1535-6108, 05/2015, Volume 27, Issue 5, pp. 658 - 670
Journal Article
Journal Article